Cardiac allograft vasculopathy prevention: Difference between revisions
No edit summary |
|||
| Line 10: | Line 10: | ||
===Optimization of Immunosuppressive Therapy=== | ===Optimization of Immunosuppressive Therapy=== | ||
Options for immunosuppressive therapy for prevention of CAV include <ref name="pmid16686747">{{cite journal| author=Mehra MR| title=Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. | journal=Am J Transplant | year= 2006 | volume= 6 | issue= 6 | pages= 1248-56 | pmid=16686747 | doi=10.1111/j.1600-6143.2006.01314.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16686747 }} </ref>: | Options for immunosuppressive therapy for prevention of CAV include <ref name="pmid16686747">{{cite journal| author=Mehra MR| title=Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. | journal=Am J Transplant | year= 2006 | volume= 6 | issue= 6 | pages= 1248-56 | pmid=16686747 | doi=10.1111/j.1600-6143.2006.01314.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16686747 }} </ref>: | ||
* [[Sirolimus]] ([[Rapamycin]]) | |||
* [[Everolimus]], a [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Rapamycin derivative]] | |||
* [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Calcineurin inhibitors]], such as | * [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Calcineurin inhibitors]], such as | ||
** [[Cyclosporine]] | ** [[Cyclosporine]] | ||
** [[Tacrolimus]] | ** [[Tacrolimus]] | ||
* [[Corticosteroids]] | * [[Corticosteroids]] | ||
* [[Mycophenolate mofetil]] | * [[Mycophenolate mofetil]] | ||
Revision as of 21:07, 9 October 2014
|
Cardiac allograft vasculopathy Microchapters |
|
Differentiating Cardiac allograft vasculopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cardiac allograft vasculopathy prevention On the Web |
|
American Roentgen Ray Society Images of Cardiac allograft vasculopathy prevention |
|
Directions to Hospitals Treating Cardiac allograft vasculopathy |
|
Risk calculators and risk factors for Cardiac allograft vasculopathy prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, it has been suggested that preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy. However, the best preventative strategy to delay development of CAV is yet to be determined.
Optimization of Immunosuppressive Therapy
Options for immunosuppressive therapy for prevention of CAV include [1]:
- Sirolimus (Rapamycin)
- Everolimus, a Rapamycin derivative
- Calcineurin inhibitors, such as
- Corticosteroids
- Mycophenolate mofetil
Calcineurin inhibitors
The use of calcineurin inhibitors i.e cyclosporin and tacrolimus have not been shown to lower the risk of developing CAV. This suggests that other immunological pathways may exists that play a role in the pathogenesis of CAV.
References
- ↑ Mehra MR (2006). "Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy". Am J Transplant. 6 (6): 1248–56. doi:10.1111/j.1600-6143.2006.01314.x. PMID 16686747.